P.G. Nuciforo - 2Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO),

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 35 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

223P Tumor Whole Genome Sequencing-Based Ultrasensitive Ctdna Analysis As an Early Biomarker for Clinical Outcome in Immune Checkpoint Inhibitor (ICI) Phase I Clinical Trials (ph1) and a Tool for Beyond Progressive Disease by Irecist

R.D.A. Toledo, A.M. Calahorro García, A.B. Moreno,O. Mirallas,V. Galvao,G. Alonso Casal,M. Vieito, I. Braña,A. Oberoi,M.J. Lostes Bardaji, K.C. Keough, F. Navarro, J. Jimenez, A. Mel Olano,P.G. Nuciforo, C. Abbott, J.L. Pugh, R. Chen, S. Boyle, E. Garralda

Annals of Oncology (2024)

引用0浏览0引用

38P Spatial Analysis of the Tumor Microenvironment in Hormone Receptor-Positive (HR+) Young Women Breast Cancer (YWBC) from a Parity and Lactation Perspective

M. Sanso,L. Sanz Gomez, T. Gorgal,O. Cordoba, P. Martinez,R. Fasani,A. Suñol, F. Gonzalez,C. Ortiz,A. Perello,G. Matheu, J. Jimenez,P.G. Nuciforo,C. Saura Manich

ESMO Open (2024)

引用0浏览0引用

579P Intratumoral Fusobacterium As Prognostic Factor in Early Stage Colorectal Cancer: Results of the FUSOMAP Study

P.G. Nuciforo, F. Moratalla Navarro,I. Baraibar Argota, L. Alonso,G. serna,J. Vidal Barrull, L. Aguilera Castro,N. Mulet Margalef,A. Fernandez Montes, M. Cuatrecasas, I. Gardeazabal Gonzalez, E. Gonzalez,P. García Alfonso,S. Rosello Keranen,R. Comas, N. Bayo Puxan,R. FASANI, M. Obon,M.E. Elez Fernandez, V. Moreno Aguado

Annals of Oncology (2024)

引用0浏览0引用

123P Pan-cancer Homologous Recombination Deficiency (HRD) Evaluation in Patients Enrolled in a Routine Molecular Screening Program

P. Romero-Lozano,A. Hernando Calvo, E. Castillo, D.G. Lo Giacco, M. Vila-Casadesús, M. Gómez, G. Buono, V. Bach, M. Pereira, A. Onieva, A. Martin,J. Matito,P.G. Nuciforo, E. Garralda, E. Felip,C. Saura Manich, J.C. Galceran, C. Garcia Duran, J. Tabernero, A. Vivancos

Annals of Oncology (2024)

引用0浏览0引用

10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial